Millenia Hope Inc. FOR IMMEDIATE RELEASE MILLENIA HOPE RECEIVES SELLING AUTHORIZATION FOR MALAREXTM FROM THE REPUBLIC OF TOGO.

MONTREAL, Canada (August 28th, 2002) -- Millenia Hope Inc., a Biotech Corporation (MLHP-OTC:BB) (Berlin Stock Exchange -- MLF), is pleased to announce that, following the reception of selling authorizations for the Republic of Guinea (Conakry), certificate number: 253 MS-DNPL-SGG and the Republic of Congo (Brazzaville), certificate number: 0-165 MSSAH-DGS-SPHL-M-SA, we have received selling authorization from the Republic of Togo, certificate number: 0266-02-MS-ASPFPE-DES-DPLET. Our representative in Togo, Sud Pharm based in the capital, Lome, will handle the sales and distribution of Malarextm.

Millenia Hope pursues its drug implementation program in Africa, the continent most adversely affected by malaria. Selling authorization is the essential final step to allow us to introduce Malarex to those populations with the most dire need for effective anti malarial products", declared Mr. Dominique Morisot, President and CEO.

About Millenia Hope:

Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.

Safe Harbour Statement:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as forward-looking statements". Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.

For further information, contact:

Mr. Dominique Morisot, President and CEO
Millenia Hope Inc.
Tel: (514) 846-5757             
E-mail: dmorisot@milleniahope.com
Web site: www.milleniahope.com